Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
1.910
0.00 (0.00%)
At close: Apr 28, 2026, 4:00 PM EDT
1.940
+0.030 (1.57%)
After-hours: Apr 28, 2026, 7:59 PM EDT
Esperion Therapeutics Employees
Esperion Therapeutics had 294 employees as of December 31, 2025. The number of employees decreased by 10 or -3.29% compared to the previous year.
Employees
294
Change (1Y)
-10
Growth (1Y)
-3.29%
Revenue / Employee
$1,371,207
Profits / Employee
-$77,150
Market Cap
491.64M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Canopy Growth | 960 |
| Emergent BioSolutions | 900 |
| Organogenesis Holdings | 854 |
| Kamada | 462 |
| Evolus | 334 |
| Akebia Therapeutics | 194 |
| Aquestive Therapeutics | 147 |
| Ironwood Pharmaceuticals | 100 |
ESPR News
- 5 days ago - Esperion to Report First Quarter 2026 Financial Results on May 7 - GlobeNewsWire
- 15 days ago - Esperion Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 26 days ago - Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics - GlobeNewsWire
- 26 days ago - Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) - GlobeNewsWire
- 6 weeks ago - Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia - GlobeNewsWire
- 6 weeks ago - Esperion Therapeutics Transcript: The Citizens Life Sciences Conference 2026 - Transcripts
- 7 weeks ago - Esperion Therapeutics Earnings Call Transcript: Q4 2025 - Transcripts
- 7 weeks ago - Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire